Dr Jonathan Rosenberg speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the preliminary durability results of the EV-103 study of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

He reports that there was an updated response rate of 73% for untreated patients, which is exceedingly high for what we expect for these patients, and that the median progression free survival was 12.3 months.

Dr Rosenberg also mentions that the side effects profile is not too dissimilar to either drug by itself sand that there does not seem to be synergistic toxicities.